Skip to content

Study · Non-randomized trial · n = 86 · 2005

5 results

Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas.

Di Lieto A, De Falco M, Pollio F, Mansueto G, Salvatore G, Somma P, Ciociola F, De Rosa G, Staibano S

Journal of the Society for Gynecologic Investigation1 Feb 2005Cited by 35 (Europe PMC)

PMID15695108 (opens in a new tab)DOI10.1016/j.jsgi.2004.10.008 (opens in a new tab)PepBankPUB-15695108
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialMechanism

    In women with uterine myomas, bFGF, VEGF, and PDGF immunoexpression decreased in leuprolide-treated myomas compared with untreated myomas.

    In plain wordsGrowth-factor expression decreased in fibroids from leuprolide-treated women compared with untreated women.

    Peptide
    Leuprolide
    Outcome
    DecreaseGrowth-factor immunoexpression
    Study

    n = 86

    Comparator
    Untreated patients
    Outcome group
    Receptor activity and mechanism · Reproductive and sexual health
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The immunoexpression of bFGF, VEGF, and PDGF decreased in treated myomas, together with the total number of vessels and the angiogenetic vessels.
    2 context sentences
    Summary · context
    The immunoexpression of bFGF, VEGF, and PDGF and of the endothelial markers CD34 and CD105, as well as the vascular pattern, were studied in leiomyomas, comparing treated and untreated patients.
    Summary · context
    Thirty-one women were treated with leuprolide acetate for 3 months; 55 untreated patients formed the control group.
  2. 02HumanNon-randomized trialMechanism

    In women with uterine myomas, total vessel numbers decreased in leuprolide-treated myomas compared with untreated myomas.

    In plain wordsFibroids from leuprolide-treated women had fewer vessels than fibroids from untreated women.

    Peptide
    Leuprolide
    Outcome
    DecreaseTotal vessel number
    Study

    n = 86

    Comparator
    Untreated patients
    Outcome group
    Receptor activity and mechanism · Reproductive and sexual health
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The immunoexpression of bFGF, VEGF, and PDGF decreased in treated myomas, together with the total number of vessels and the angiogenetic vessels.
    2 context sentences
    Summary · context
    The immunoexpression of bFGF, VEGF, and PDGF and of the endothelial markers CD34 and CD105, as well as the vascular pattern, were studied in leiomyomas, comparing treated and untreated patients.
    Summary · context
    Thirty-one women were treated with leuprolide acetate for 3 months; 55 untreated patients formed the control group.
  3. 03HumanNon-randomized trialMechanism

    In women with uterine myomas, angiogenetic vessels decreased in leuprolide-treated myomas compared with untreated myomas.

    In plain wordsFibroids from leuprolide-treated women had fewer angiogenetic vessels than fibroids from untreated women.

    Peptide
    Leuprolide
    Outcome
    DecreaseAngiogenetic vessels
    Study

    n = 86

    Comparator
    Untreated patients
    Outcome group
    Receptor activity and mechanism · Reproductive and sexual health
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The immunoexpression of bFGF, VEGF, and PDGF decreased in treated myomas, together with the total number of vessels and the angiogenetic vessels.
    2 context sentences
    Summary · context
    The immunoexpression of bFGF, VEGF, and PDGF and of the endothelial markers CD34 and CD105, as well as the vascular pattern, were studied in leiomyomas, comparing treated and untreated patients.
    Summary · context
    Thirty-one women were treated with leuprolide acetate for 3 months; 55 untreated patients formed the control group.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with uterine myomas, hematologic parameters improved after leuprolide treatment.

    In plain wordsBlood parameters improved after leuprolide treatment in women with uterine fibroids.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedHematologic parameters
    Study

    n = 31

    Outcome group
    Hematologic parameters · Whole body
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Hematologic parameters improved and uterine volumes decreased after GnRH-a treatment.
    1 context sentence
    Summary · context
    Thirty-one women were treated with leuprolide acetate for 3 months; 55 untreated patients formed the control group.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with uterine myomas, uterine volume decreased after leuprolide treatment.

    In plain wordsUterine volume decreased after leuprolide treatment in women with uterine fibroids.

    Peptide
    Leuprolide
    Outcome
    DecreaseUterine volume
    Study

    n = 31

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Hematologic parameters improved and uterine volumes decreased after GnRH-a treatment.
    1 context sentence
    Summary · context
    Thirty-one women were treated with leuprolide acetate for 3 months; 55 untreated patients formed the control group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.